Specifications tableSubjectCancer ResearchSpecific subject areaMalignant melanoma, anti-PD-1, biomarkerType of dataTable and FigureHow data were acquiredDownload from GEO database, Microscope and surveyData formatRaw\
AnalyzedParameters for data collectionThe downloaded raw data is standardized before data analysis. Microscope photos should be of sufficient resolution.Description of data collectionData for melanoma patients who did not receive anti-PD-1 therapy were obtained from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were download from the GEO database (GSE78220). Information of 13 melanoma patients who had failed prior chemotherapy and treated in the Tianjin Medical University Cancer Institute & Hospital between July 2015 and December 2018 was collected.Data source locationDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Hospital & Institute, Tianjin 300,060, ChinaData accessibilityWith the articleRelated research articleTing, L. et al. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters, 2020, 477(2020):19--30.

Value of the data {#sec0001}
=================

•The present data show the characteristics of melanoma patients with or without anti-PD-1 treatment from RNA and protein levels. The data might contain valuable information on the clinical use of anti-PD-1 agents.•These data are preliminary exploration of combined IGFBP2 and PD-L1 as reliable biomarkers to predict the efficacy of anti-PD-1/PD-L1 therapy. These data and methods provide direction for further expanding research and other reliable biomarkers.

1. Data description {#sec0002}
===================

These data show the expression characteristics of malignant melanoma patients with or without anti-PD-1 treatment at RNA and protein levels. As for melanoma patients who did not receive anti-PD-1 treatment, data were collected from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. The multivariate analysis data are shown in [Table 1](#tbl0001){ref-type="table"}. The RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were obtained from the GEO database (GSE78220) (Supplementary Information 1). According to the response to anti-PD-1 treatment, patients were divided into two groups: response and non-response group. Bioinformatic analysis are shown in [Fig. 1](#fig0001){ref-type="fig"}. The ROC analysis of the data in [Table 2](#tbl0002){ref-type="table"} corresponds to [Fig 1](#fig0001){ref-type="fig"}D. The clinical characteristics of 13 Chinese melanoma patients who received anti-PD-1 treatment are shown [Table 3](#tbl0003){ref-type="table"}. The efficacy evaluation and protein expression characteristics of anti-PD-1 treatment were shown in [Figs. 2](#fig0002){ref-type="fig"} and [3](#fig0003){ref-type="fig"}. Furthermore, [Fig. 2](#fig0002){ref-type="fig"} and [Table 3](#tbl0003){ref-type="table"} are related, and [Fig. 3](#fig0003){ref-type="fig"} is representing an IHC summary on subset of patients that have been listed in [Table 2](#tbl0002){ref-type="table"}.Table 1Multivariate analysis of the prognostic values of IGFBP2 and PD-L1 protein expression in malignant melanoma patients.Table 1ParameterOverall survivalHR95% CIPBoth high2.5121.206--5.2320.014IGFBP2 high +PD-L1 low1.3380.476--3.7620.581IGFBP2 low +PD-L1 high1.4870.062--3.3370.336Both low------Fig. 1The mRNA expression levels of IGFBP2 and PD-L1 and the predict role of anti-PD-1 treatment. (A) The expression levels of PD-L1-related genes, including PD-L1 (CD274) itself, in 28 melanoma patients (GSE78220). The mRNA expression levels of genes with hypothetical roles in modulating response to anti-PD-1 therapy from RNA-seq data GSE78220 of 28 melanoma patients who received anti-PD-1 treatment. RESPONSE: response to anti-PD-1 treatment. The red box indicates a positive response. (B) Differential expression of PD-L1 in mRNA levels in melanoma from responders (R) and non-responders (NR). (C) Fisher\'s exact test were used to indicates the efficiency of anti-PD-1treatment on different groups of melanoma patients. (*p* \< 0.05). (D) ROC curve of shows the AUC of both high PD-L1 and high IGFBP2 mRNA group, high IGFBP2 mRNA expression group and high PD-L1 mRNA expression group (AUC: 0.667 vs. 0.536 vs. 0.536).Fig 1Table 2The ROC analysis the response for IGFBP2, PD-L1 and TWO---HIGH groups to anti-PD-1 treatment.Table 2VariablesAUC95% CICut-offSensitivity (%)Specificity (%)IGFBP20.53634.4--72.81.5053.853.3PD-L10.53634.4--72.81.5053.853.3TWO---HIGH0.66754.3--79.01.5010033.3Table 3Clinical characteristics of 13 Chinese melanoma patients in stage IV who received anti-PD-1 treatment.Table 3PatientSexAgeTumor siteMetastasis sitePD-1 antibodyCyclesEfficacyPD-L1 expressionIGFBP2 expression1Female57MucousLymph nodeOpdivo2SDLowLow2Male64MucousLeft adrenal glandKeytruda4PDHighLow3Male61DermaRight lungKeytruda2SDHighHigh4Female42DermaRight adrenal glandKeytruda5PDLowHigh5Male60DermaRight lungKeytruda4PRHighHigh6Female57undetermined originRight subaxillaryKeytruda2PDLowHigh7Male53DermaLymph nodeOpdivo2SD----8Female53MucousLymph nodeKeytruda3------9Female76DermaLeft lungKeytruda21----10Female59MucousLymph nodeKeytruda4------11Female50MucousLiverOpdivo8------12Female57MucousLungKeytruda2------13Male62DermaLiverKeytruda7------[^2]Fig. 2The efficacy of anti-PD-1 treatment and the expression of IGFBP2, EGFR and PD-L1. (A) Changes in the size of the target lesions after anti-PD-1 treatment compared with the baseline in 6 melanoma patients with measurable lesions. The green line shows that the target lesions shrank more than 30% by the final measurement. The red lines show that the target lesions increased by 20% by the final measurement. The yellow lines represent the target lesions that changed between 20% and −30%. One patient achieved PR, two patients achieved SD and three patients suffered from PD. (B) The maximum change in the target lesions in 6 melanoma patients treated with Keytruda or Opdivo was evaluated by RECIST 1.1. (C, D, E) The pathological data of one patient with lung metastatic melanoma and response to anti-PD-1 treatment showed high IGFBP2 (C) EGFR (D) and PD-L1 (E) expression. (F, G, H, I) The repeated chest CT showed the PR patient with increased volumes of lung metastases at 2.6 months (F-G) and then a gradual decrease (H-I).Fig 2Fig. 3The IHC staining of 6 melanoma patients with IGFBP2 and PD-L1 expression. Patient 1 showed low IGFBP2 and low PD-L1 expression; Patient 2 showed low IGFBP2 and high PD-L1 expression; Patient 3 showed high IGFBP2 and high PD-L1 expression; Patient 4 showed high IGFBP2 and low PD-L1 expression; Patient 5 showed high IGFBP2 and high PD-L1 expression; Patient 6 showed high IGFBP2 and low PD-L1 expression.Fig 3

2. Experimental design, materials, and methods {#sec0003}
==============================================

2.1. Bioinformatic analysis of RNA sequencing data of melanoma patients with anti-PD-1 therapy (GSE78220) {#sec0004}
---------------------------------------------------------------------------------------------------------

Analysis of RNA sequencing data from the GEO database (GSE78220), which includes 28 patients with malignant melanoma who received anti-PD-1 treatment [@bib0001]. According to the response to anti-PD-L1 treatment, patients were divided into two groups: response and non-response groups. Cluster analysis of RNA expression was performed using R (package pheatmap). The difference in the mRNA expression of PD-L1 was analyzed by the Boxplot (R ggplot2 package). According to the median mRNA levels of IGFBP2 and PD-L1, the 28 patients were divided into four groups (high IGFBP2+high PD-L1, high IGFBP2+low PD-L1, low IGFBP2+high PD-L1 and low IGFBP2+low PD-L1). Differences among the four groups were analyzed by Fisher exact test. \**p*\<0.05, \*\**p*\<0.01, and \*\*\**p*\<0.001.

2.2. Anti-PD-1 treatment efficacy and assessment {#sec0005}
------------------------------------------------

Data were collected from 13 melanoma patients who had failed prior chemotherapy and treated in the Tianjin Medical University Cancer Institute & Hospital between July 2015 and December 2018. These patients had unresectable stage III or IV malignant melanoma. The therapeutic dose of Keytruda (pembrolizumab) was 2 mg/kg, once every three weeks, and the therapeutic dose of Opdivo (nivolumab) was 3 mg/kg, once every two weeks. The cancer immunotherapy response was captured by Response Evaluation Criteria in Solid Tumors (RECIST) [@bib0002],[@bib0003]. Tumors were reduced by at least 30% for more than 4 weeks is considered a partial response (PR). The maximum diameter of the target lesion increased by at least 20% or new lesions were identified as disease progression (PD). The sum of the maximum diameter of the target lesion reduced to less than PR or increased to less than PD was considered stable disease (SD).

Appendix. Supplementary materials {#sec0007}
=================================
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